Spinal muscular atrophy (SMA) is a severe neurological disease for which there is presently no cure, although current therapies can alleviate symptoms. In the search for better treatment options, ...

England will add SMA testing to its newborn screening program from October 2026, expanding nationwide by October 2027 to help ...

Oral risdiplam (Evrysdi, Genentech) started in the first 6 weeks of life let most infants with presymptomatic spinal muscular atrophy (SMA) reach motor milestones typical of healthy babies, results of ...

Campaigners hail ‘landmark moment’ in early detection and treatment of rare muscle-wasting disease ...

Spinal muscular atrophy (SMA) is a terrible disease in which a genetic mutation causes certain nerves responsible for sending signals to muscles to degenerate. This leads to muscles wasting away, and ...

A new clinical trial has revealed encouraging results for a muscle-targeting therapy aimed at improving motor function in children and adolescents with spinal muscular atrophy, according to a study ...

Muscle wasting in chronic kidney disease (CKD) is a common yet underrecognized complication, tightly intertwined with ...

With the global population ageing rapidly, sarcopenia, a condition that affects millions of older adults and severely diminishes their quality of life, is emerging as an urgent public health issue.

With the intensification of global population aging, muscle atrophy, characterized by the loss of muscle mass and function, has become an important health issue affecting the elderly. Researchers have ...

Late-stage trial data for Roche’s drug against muscle-wasting Elevidys showed positive results after two years of treatment for male patients aged 4 or older with Duchenne muscular dystrophy. The data ...